Related Experiment Video
Updated: Sep 9, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Aligning organ-specific toxicities with formulation strategies: a rational design approach to chemotherapy
1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou 510275, China.
None:
Chemotherapy-induced toxicity remains a persistent challenge in oncology, where multi-organ injury continues to limit clinical outcomes despite decades of drug optimization and formulation innovation. Although mechanistic studies have elucidated key pathways of damage, current formulation strategies often overlook organ-specific pathophysiology, resulting in nonspecific mitigation approaches. This review fills a methodological gap by introducing a toxicity-informed framework that integrates organ-specific injury mechanisms with formulation design principles to support rational chemotherapy optimization. By analyzing toxicities in key organs with delivery system advances-including nanocarriers, prodrug designs, and stimuli-responsive platforms-we construct a decision-making flowchart to guide rational formulation selection based on toxicity profiles. Representative new drugs such as Padcev® and Zepzelca® are examined to highlight how discordance between toxicity mechanism and delivery design leads to avoidable adverse effects. This framework bridges mechanistic toxicology with formulation logic, aiming to facilitate more targeted, organ-aware chemotherapeutic design. In this review, we synthesize over 240 publications published up to June 2025, we consolidate current evidence into a unified decision-making model that aligns toxicity mechanisms with formulation strategies. This effort lays a foundation for future integration of mechanism-based formulation frameworks into more systematic and predictive models for chemotherapeutic design and clinical translation.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
09:56Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...